Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Akero Therapeutics, Inc. (AKRO) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Akero Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1744659.
Total stock buying since 2019: $122,639,119.
Total stock sales since 2019: $244,965,606.
Total stock option exercises since 2019: $26,916,135.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 400,000 | $18,387,920 | 783,368 | $38,925,730 | 528,475 | $8,859,234 |
| 2024 | 0 | $0 | 903,699 | $26,910,701 | 818,995 | $12,138,327 |
| 2023 | 800,000 | $22,531,199 | 638,727 | $30,054,552 | 612,127 | $2,283,186 |
| 2022 | 0 | $0 | 2,521,334 | $105,229,431 | 485,960 | $2,866,368 |
| 2021 | 0 | $0 | 333,324 | $8,097,709 | 126,500 | $653,302 |
| 2020 | 830,000 | $29,880,000 | 1,109,902 | $24,743,439 | 120,196 | $115,718 |
| 2019 | 3,240,000 | $51,840,000 | 462,597 | $11,004,044 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-09 | 0 | $0 | 12,500 | $585,387 | 12,500 | $263,750 |
| 2025-08 | 0 | $0 | 58,000 | $2,822,346 | 30,600 | $599,414 |
| 2025-07 | 0 | $0 | 54,500 | $2,820,090 | 22,500 | $462,325 |
| 2025-06 | 0 | $0 | 112,906 | $6,138,914 | 49,500 | $1,041,865 |
| 2025-05 | 0 | $0 | 64,500 | $2,715,979 | 34,500 | $811,190 |
| 2025-04 | 0 | $0 | 76,573 | $2,914,162 | 46,573 | $982,690 |
| 2025-03 | 200,000 | $8,787,920 | 107,651 | $4,733,162 | 23,500 | $494,620 |
| 2025-02 | 0 | $0 | 68,750 | $3,714,028 | 28,750 | $606,625 |
| 2025-01 | 200,000 | $9,600,000 | 227,988 | $12,481,662 | 280,052 | $3,596,755 |
| 2024-12 | 0 | $0 | 70,602 | $2,204,558 | 40,324 | $843,148 |
| 2024-11 | 0 | $0 | 193,628 | $6,209,905 | 183,628 | $3,669,292 |
| 2024-10 | 0 | $0 | 167,110 | $5,171,040 | 155,974 | $2,884,534 |
| 2024-09 | 0 | $0 | 18,961 | $517,297 | 14,842 | $9,125 |
| 2024-08 | 0 | $0 | 117,385 | $3,178,137 | 136,923 | $1,714,283 |
| 2024-07 | 0 | $0 | 201,666 | $5,464,256 | 191,658 | $1,343,329 |
| 2024-06 | 0 | $0 | 24,015 | $526,952 | 0 | $0 |
| 2024-05 | 0 | $0 | 5,000 | $100,750 | 0 | $0 |
| 2024-04 | 0 | $0 | 5,000 | $123,379 | 0 | $0 |
| 2024-03 | 0 | $0 | 100,332 | $3,414,427 | 95,646 | $1,674,616 |
| 2023-12 | 150,000 | $2,832,650 | 36,285 | $750,724 | 32,392 | $206,012 |
| 2023-11 | 50,000 | $844,849 | 30,000 | $440,250 | 0 | $0 |
| 2023-10 | 0 | $0 | 25,490 | $1,233,889 | 25,490 | $169,339 |
| 2023-09 | 400,000 | $10,400,000 | 34,024 | $1,693,174 | 30,000 | $190,800 |
| 2023-08 | 50,000 | $2,133,000 | 30,745 | $1,368,606 | 45,745 | $204,763 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | Young Jonathan (Chief Operating Officer) | Sale | 12,500 | 46.83 | 585,387 |
| 2025-09-02 | Young Jonathan (Chief Operating Officer) | Option Ex | 12,500 | 21.10 | 263,750 |
| 2025-08-15 | Gangloff Scott A. (Chief Technology Officer) | Option Ex | 2,600 | 19.62 | 51,012 |
| 2025-08-12 | Young Jonathan (Chief Operating Officer) | Sale | 12,500 | 48.02 | 600,275 |
| 2025-08-12 | Young Jonathan (Chief Operating Officer) | Option Ex | 12,500 | 21.10 | 263,750 |
| 2025-08-12 | Henderson Jane | Sale | 3,000 | 47.46 | 142,371 |
| 2025-08-12 | Henderson Jane | Option Ex | 3,000 | 7.01 | 21,027 |
| 2025-08-11 | Cheng Andrew (President and CEO) | Sale | 30,000 | 48.79 | 1,463,700 |
| 2025-08-05 | Rolph Timothy (Chief Scientific Officer) | Sale | 12,500 | 49.28 | 616,000 |
| 2025-08-05 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 12,500 | 21.09 | 263,625 |
| 2025-07-16 | Yale Catriona (Chief Development Officer) | Sale | 10,000 | 53.17 | 531,700 |
| 2025-07-16 | Yale Catriona (Chief Development Officer) | Option Ex | 10,000 | 19.87 | 198,700 |
| 2025-07-10 | Cheng Andrew (President and CEO) | Sale | 30,000 | 51.15 | 1,534,530 |
| 2025-07-07 | Rolph Timothy (Chief Scientific Officer) | Sale | 12,500 | 51.85 | 648,100 |
| 2025-07-07 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 12,500 | 21.09 | 263,625 |
| 2025-07-01 | Lamy Patrick (Senior VP, Commercial Strategy) | Sale | 2,000 | 52.88 | 105,760 |
| 2025-06-20 | Lamy Patrick (Senior VP, Commercial Strategy) | Sale | 875 | 54.59 | 47,766 |
| 2025-06-18 | Young Jonathan (Chief Operating Officer) | Sale | 1,453 | 54.84 | 79,682 |
| 2025-06-18 | Rolph Timothy (Chief Scientific Officer) | Sale | 1,129 | 54.84 | 61,914 |
| 2025-06-18 | Yale Catriona (Chief Development Officer) | Sale | 1,633 | 54.84 | 89,553 |
| 2025-06-18 | White William Richard (Chief Financial Officer) | Sale | 1,634 | 54.84 | 89,608 |
| 2025-06-18 | Cheng Andrew (President and CEO) | Sale | 6,620 | 54.84 | 363,040 |
| 2025-06-18 | Gangloff Scott A. (Chief Technology Officer) | Sale | 848 | 54.84 | 46,504 |
| 2025-06-16 | Lamy Patrick (Senior VP, Commercial Strategy) | Sale | 2,000 | 54.45 | 108,908 |
| 2025-06-16 | Lamy Patrick (Senior VP, Commercial Strategy) | Option Ex | 2,000 | 19.87 | 39,740 |
| 2025-06-16 | Yale Catriona (Chief Development Officer) | Sale | 10,000 | 54.70 | 546,990 |
| 2025-06-16 | Yale Catriona (Chief Development Officer) | Option Ex | 10,000 | 21.10 | 211,000 |
| 2025-06-10 | Lamy Patrick (Senior VP, Commercial Strategy) | Sale | 919 | 54.00 | 49,625 |
| 2025-06-10 | Young Jonathan (Chief Operating Officer) | Sale | 2,493 | 53.99 | 134,604 |
| 2025-06-10 | Rolph Timothy (Chief Scientific Officer) | Sale | 2,358 | 54.00 | 127,322 |
| 2025-06-10 | Yale Catriona (Chief Development Officer) | Sale | 2,803 | 54.00 | 151,350 |
| 2025-06-10 | White William Richard (Chief Financial Officer) | Sale | 2,804 | 53.99 | 151,401 |
| 2025-06-10 | Cheng Andrew (President and CEO) | Sale | 37,837 | 54.04 | 2,044,560 |
| 2025-06-06 | Rolph Timothy (Chief Scientific Officer) | Sale | 25,000 | 55.04 | 1,376,000 |
| 2025-06-06 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 25,000 | 21.09 | 527,375 |
| 2025-06-05 | Rolph Timothy (Chief Scientific Officer) | Sale | 12,500 | 53.61 | 670,087 |
| 2025-06-05 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 12,500 | 21.10 | 263,750 |
| 2025-05-22 | Lamy Patrick (Senior VP, Commercial Strategy) | Sale | 4,000 | 50.00 | 200,000 |
| 2025-05-22 | Lamy Patrick (Senior VP, Commercial Strategy) | Option Ex | 4,000 | 44.37 | 177,480 |
| 2025-05-15 | Yale Catriona (Chief Development Officer) | Sale | 10,000 | 39.19 | 391,880 |
| 2025-05-15 | Yale Catriona (Chief Development Officer) | Option Ex | 10,000 | 21.10 | 211,000 |
| 2025-05-12 | Cheng Andrew (President and CEO) | Sale | 30,000 | 41.32 | 1,239,510 |
| 2025-05-07 | Lamy Patrick (Senior VP, Commercial Strategy) | Sale | 8,000 | 42.53 | 340,264 |
| 2025-05-07 | Lamy Patrick (Senior VP, Commercial Strategy) | Option Ex | 8,000 | 19.87 | 158,960 |
| 2025-05-06 | Rolph Timothy (Chief Scientific Officer) | Sale | 12,500 | 43.55 | 544,325 |
| 2025-05-06 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 12,500 | 21.10 | 263,750 |
| 2025-04-24 | Rolph Timothy (Chief Scientific Officer) | Sale | 18,750 | 41.03 | 769,311 |
| 2025-04-24 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 18,750 | 21.10 | 395,625 |
| 2025-04-15 | Yale Catriona (Chief Development Officer) | Sale | 9,073 | 38.21 | 346,679 |
| 2025-04-15 | Yale Catriona (Chief Development Officer) | Option Ex | 9,073 | 21.10 | 191,440 |
| 2025-04-10 | Cheng Andrew (President and CEO) | Sale | 30,000 | 35.23 | 1,056,780 |
| 2025-04-07 | Rolph Timothy (Chief Scientific Officer) | Sale | 6,250 | 36.56 | 228,518 |
| 2025-04-07 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 6,250 | 21.10 | 131,875 |
| 2025-03-27 | Graham G. Walmsley | Buy | 50,000 | 43.55 | 2,177,700 |
| 2025-03-26 | Graham G. Walmsley | Buy | 58,691 | 43.01 | 2,524,417 |
| 2025-03-25 | Graham G. Walmsley | Buy | 91,309 | 44.75 | 4,085,803 |
| 2025-03-17 | Yale Catriona (Chief Development Officer) | Sale | 10,000 | 44.87 | 448,740 |
| 2025-03-17 | Yale Catriona (Chief Development Officer) | Option Ex | 10,000 | 21.10 | 211,000 |
| 2025-03-12 | Young Jonathan (Chief Operating Officer) | Sale | 607 | 44.88 | 27,242 |
| 2025-03-12 | Rolph Timothy (Chief Scientific Officer) | Sale | 516 | 44.88 | 23,158 |
| 2025-03-12 | Yale Catriona (Chief Development Officer) | Sale | 614 | 44.88 | 27,556 |
| 2025-03-12 | White William Richard (Chief Financial Officer) | Sale | 676 | 44.88 | 30,338 |
| 2025-03-12 | Cheng Andrew (President and CEO) | Sale | 1,738 | 44.88 | 78,001 |
| 2025-03-10 | Cheng Andrew (President and CEO) | Sale | 30,000 | 42.03 | 1,260,900 |
| 2025-03-05 | Rolph Timothy (Chief Scientific Officer) | Sale | 12,500 | 44.65 | 558,137 |
| 2025-03-05 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 12,500 | 21.10 | 263,750 |
| 2025-03-04 | Young Jonathan (Chief Operating Officer) | Sale | 50,000 | 44.62 | 2,231,000 |
| 2025-03-03 | Lamy Patrick (Senior VP, Commercial Strategy) | Sale | 1,000 | 48.09 | 48,090 |
| 2025-03-03 | Lamy Patrick (Senior VP, Commercial Strategy) | Option Ex | 1,000 | 19.87 | 19,870 |
| 2025-02-18 | Yale Catriona (Chief Development Officer) | Sale | 10,000 | 50.21 | 502,120 |
| 2025-02-18 | Yale Catriona (Chief Development Officer) | Option Ex | 10,000 | 21.10 | 211,000 |
| 2025-02-10 | Cheng Andrew (President and CEO) | Sale | 30,000 | 53.74 | 1,612,080 |
| 2025-02-05 | Rolph Timothy (Chief Scientific Officer) | Sale | 18,750 | 56.62 | 1,061,718 |
| 2025-02-05 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 18,750 | 21.10 | 395,625 |
| 2025-02-03 | Young Jonathan (Chief Operating Officer) | Sale | 10,000 | 53.81 | 538,110 |
| 2025-01-30 | Graham G. Walmsley | Buy | 200,000 | 48.00 | 9,600,000 |
| 2025-01-27 | Lamy Patrick (Senior VP, Commercial Strategy) | Sale | 5,000 | 57.03 | 285,150 |
| 2025-01-27 | Lamy Patrick (Senior VP, Commercial Strategy) | Option Ex | 4,000 | 19.87 | 79,480 |
| 2025-01-27 | Rolph Timothy (Chief Scientific Officer) | Sale | 31,250 | 55.78 | 1,743,218 |
| 2025-01-27 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 31,250 | 20.48 | 640,156 |
| 2025-01-27 | Yale Catriona (Chief Development Officer) | Sale | 102,664 | 56.04 | 5,753,254 |
| 2025-01-27 | Yale Catriona (Chief Development Officer) | Option Ex | 102,664 | 15.23 | 1,536,849 |
| 2025-01-27 | Cheng Andrew (President and CEO) | Sale | 30,000 | 55.66 | 1,669,800 |
| 2025-01-24 | Young Jonathan (Chief Operating Officer) | Option Ex | 43,064 | 6.36 | 274,059 |
| 2025-01-23 | Cheng Andrew (President and CEO) | Option Ex | 50,000 | .61 | 30,750 |
| 2025-01-02 | Young Jonathan (Chief Operating Officer) | Sale | 10,000 | 28.03 | 280,330 |
| 2024-12-17 | Rolph Timothy (Chief Scientific Officer) | Sale | 3,800 | 31.10 | 118,172 |
| 2024-12-17 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 3,800 | 19.87 | 75,506 |
| 2024-12-16 | Lamy Patrick (Senior VP, Commercial Strategy) | Sale | 1,000 | 29.13 | 29,130 |
| 2024-12-16 | Yale Catriona (Chief Development Officer) | Sale | 9,074 | 29.11 | 264,116 |
| 2024-12-16 | Yale Catriona (Chief Development Officer) | Option Ex | 9,074 | 21.10 | 191,461 |
| 2024-12-10 | Lamy Patrick (Senior VP, Commercial Strategy) | Sale | 925 | 30.79 | 28,480 |
| 2024-12-10 | Young Jonathan (Chief Operating Officer) | Sale | 2,503 | 30.79 | 77,067 |
| 2024-12-10 | Rolph Timothy (Chief Scientific Officer) | Sale | 4,818 | 30.91 | 148,924 |
| 2024-12-10 | Rolph Timothy (Chief Scientific Officer) | Option Ex | 2,450 | 19.87 | 48,681 |
| 2024-12-10 | Yale Catriona (Chief Development Officer) | Sale | 2,810 | 30.79 | 86,519 |
| 2024-12-10 | White William Richard (Chief Financial Officer) | Sale | 2,817 | 30.79 | 86,735 |
| 2024-12-10 | Cheng Andrew (President and CEO) | Sale | 7,855 | 30.79 | 241,855 |
| 2024-12-02 | Young Jonathan (Chief Operating Officer) | Sale | 10,000 | 32.13 | 321,310 |
| 2024-12-02 | Cheng Andrew (President and CEO) | Sale | 25,000 | 32.09 | 802,250 |
| 2024-12-02 | Cheng Andrew (President and CEO) | Option Ex | 25,000 | 21.10 | 527,500 |
| 2024-11-15 | Yale Catriona (Chief Development Officer) | Sale | 9,061 | 28.26 | 256,045 |
| 2024-11-15 | Yale Catriona (Chief Development Officer) | Option Ex | 9,061 | 21.10 | 191,187 |
| 2024-11-06 | Yale Catriona (Chief Development Officer) | Sale | 10,000 | 35.19 | 351,890 |
| 2024-11-06 | Yale Catriona (Chief Development Officer) | Option Ex | 10,000 | .61 | 6,150 |
| 2024-11-01 | Young Jonathan (Chief Operating Officer) | Sale | 50,716 | 32.15 | 1,630,671 |
| 2024-11-01 | Young Jonathan (Chief Operating Officer) | Option Ex | 40,716 | 21.09 | 858,700 |
| 2024-11-01 | Yale Catriona (Chief Development Officer) | Sale | 15,485 | 32.62 | 505,105 |
| 2024-11-01 | Yale Catriona (Chief Development Officer) | Option Ex | 15,485 | 21.10 | 326,733 |
| 2024-11-01 | Cheng Andrew (President and CEO) | Sale | 108,366 | 31.99 | 3,466,194 |
| 2024-11-01 | Cheng Andrew (President and CEO) | Option Ex | 108,366 | 21.10 | 2,286,522 |
| 2024-10-30 | Yale Catriona (Chief Development Officer) | Sale | 4,515 | 32.53 | 146,854 |
| 2024-10-30 | Yale Catriona (Chief Development Officer) | Option Ex | 4,515 | 21.10 | 95,266 |
| 2024-10-18 | Cheng Andrew (President and CEO) | Sale | 63,539 | 31.82 | 2,022,065 |
| 2024-10-18 | Cheng Andrew (President and CEO) | Option Ex | 63,539 | 21.10 | 1,340,672 |
| 2024-10-17 | Cheng Andrew (President and CEO) | Sale | 3,103 | 31.12 | 96,559 |
| 2024-10-17 | Cheng Andrew (President and CEO) | Option Ex | 3,103 | 21.10 | 65,473 |
| 2024-10-16 | Cheng Andrew (President and CEO) | Sale | 24,992 | 31.14 | 778,150 |
| 2024-10-16 | Cheng Andrew (President and CEO) | Option Ex | 24,992 | 21.10 | 527,331 |
| 2024-10-15 | Yale Catriona (Chief Development Officer) | Sale | 14,825 | 30.71 | 455,305 |
| 2024-10-15 | Yale Catriona (Chief Development Officer) | Option Ex | 14,825 | .61 | 9,117 |
| 2024-10-14 | Young Jonathan (Chief Operating Officer) | Sale | 40,000 | 30.15 | 1,206,080 |
| 2024-10-14 | Young Jonathan (Chief Operating Officer) | Option Ex | 40,000 | 21.09 | 843,600 |
| 2024-10-14 | Yale Catriona (Chief Development Officer) | Sale | 6,136 | 30.03 | 184,257 |
| 2024-10-14 | Yale Catriona (Chief Development Officer) | Option Ex | 5,000 | .61 | 3,075 |
| 2024-10-01 | Young Jonathan (Chief Operating Officer) | Sale | 10,000 | 28.18 | 281,770 |
| 2024-09-20 | Yale Catriona (Chief Development Officer) | Sale | 5,500 | 27.65 | 152,086 |
| 2024-09-20 | Yale Catriona (Chief Development Officer) | Option Ex | 5,500 | .61 | 3,382 |
| 2024-09-18 | Yale Catriona (Chief Development Officer) | Sale | 3,871 | 27.56 | 106,684 |
| 2024-09-18 | Yale Catriona (Chief Development Officer) | Option Ex | 3,871 | .61 | 2,380 |
| 2024-09-17 | Yale Catriona (Chief Development Officer) | Sale | 2,037 | 27.55 | 56,115 |
| 2024-09-17 | Yale Catriona (Chief Development Officer) | Option Ex | 2,037 | .61 | 1,252 |
| 2024-09-16 | Yale Catriona (Chief Development Officer) | Sale | 2,485 | 27.52 | 68,374 |
| 2024-09-16 | Yale Catriona (Chief Development Officer) | Option Ex | 2,485 | .61 | 1,528 |
| 2024-09-10 | Young Jonathan (Chief Operating Officer) | Sale | 568 | 26.18 | 14,870 |
| 2024-09-10 | Rolph Timothy (Chief Scientific Officer) | Sale | 537 | 26.18 | 14,058 |
| 2024-09-10 | Yale Catriona (Chief Development Officer) | Sale | 637 | 26.18 | 16,676 |
| 2024-09-10 | White William Richard (Chief Financial Officer) | Sale | 639 | 26.18 | 16,729 |
| 2024-09-10 | Cheng Andrew (President and CEO) | Sale | 1,738 | 26.18 | 45,500 |
| 2024-09-03 | Yale Catriona (Chief Development Officer) | Sale | 949 | 27.61 | 26,205 |
| 2024-09-03 | Yale Catriona (Chief Development Officer) | Option Ex | 949 | .61 | 583 |
| 2024-08-27 | White William Richard (Chief Financial Officer) | Sale | 23,175 | 26.41 | 612,098 |
| 2024-08-27 | White William Richard (Chief Financial Officer) | Option Ex | 23,175 | 21.09 | 488,760 |
| 2024-08-26 | Yale Catriona (Chief Development Officer) | Sale | 5,200 | 27.51 | 143,072 |
| 2024-08-26 | Yale Catriona (Chief Development Officer) | Option Ex | 5,200 | .61 | 3,198 |
| 2024-08-26 | White William Richard (Chief Financial Officer) | Sale | 75,159 | 27.21 | 2,045,151 |
| 2024-08-26 | White William Richard (Chief Financial Officer) | Option Ex | 75,159 | 15.99 | 1,201,792 |
| 2024-08-23 | Yale Catriona (Chief Development Officer) | Sale | 8,851 | 27.53 | 243,641 |
| 2024-08-23 | Yale Catriona (Chief Development Officer) | Option Ex | 8,851 | .61 | 5,443 |
| 2024-08-16 | Cheng Andrew (President and CEO) | Option Ex | 24,538 | .61 | 15,090 |
Insider trading activities including stock purchases, stock sales, and option exercises of AKRO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Akero Therapeutics, Inc. (symbol AKRO, CIK number 1744659) see the Securities and Exchange Commission (SEC) website.